Equities analysts predict that GlycoMimetics Inc (NASDAQ:GLYC) will post earnings per share of ($0.34) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for GlycoMimetics’ earnings, with the highest EPS estimate coming in at ($0.30) and the lowest estimate coming in at ($0.38). GlycoMimetics reported earnings per share of ($0.33) during the same quarter last year, which would indicate a negative year over year growth rate of 3%. The company is expected to announce its next quarterly earnings results on Thursday, May 2nd.
According to Zacks, analysts expect that GlycoMimetics will report full-year earnings of ($1.19) per share for the current year, with EPS estimates ranging from ($1.82) to ($0.22). For the next fiscal year, analysts forecast that the firm will report earnings of ($1.47) per share, with EPS estimates ranging from ($1.69) to ($1.23). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for GlycoMimetics.
GlycoMimetics (NASDAQ:GLYC) last posted its quarterly earnings results on Wednesday, March 6th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.02).
NASDAQ GLYC opened at $12.46 on Friday. The company has a market cap of $537.90 million, a P/E ratio of -10.56 and a beta of 2.76. GlycoMimetics has a 1 year low of $8.29 and a 1 year high of $19.20.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP bought a new position in GlycoMimetics in the 3rd quarter valued at approximately $5,598,000. Man Group plc lifted its stake in GlycoMimetics by 627.1% in the 3rd quarter. Man Group plc now owns 411,995 shares of the biotechnology company’s stock valued at $5,933,000 after purchasing an additional 355,329 shares during the last quarter. Hudson Bay Capital Management LP lifted its stake in GlycoMimetics by 105.9% in the 4th quarter. Hudson Bay Capital Management LP now owns 350,000 shares of the biotechnology company’s stock valued at $3,315,000 after purchasing an additional 180,000 shares during the last quarter. Jefferies Group LLC bought a new position in GlycoMimetics in the 3rd quarter valued at approximately $2,458,000. Finally, Allianz Asset Management GmbH lifted its stake in GlycoMimetics by 970.6% in the 3rd quarter. Allianz Asset Management GmbH now owns 118,448 shares of the biotechnology company’s stock valued at $1,706,000 after purchasing an additional 107,384 shares during the last quarter.
GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML.
See Also: Why is the ROA ratio important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.